|
 |
 |
| 6 entries found. Viewing page 1 of 1. |
| |
| June 08, 2010 |
| The Cleveland Plain Dealer Reports Fleet Settlement Coming Soon |
| Posted By DeCarli Law |
 |
The Cleveland Plain Dealer has reported that C.B. Fleet Co. is "close to reaching a final settlement" with people across the country who say their kidneys were harmed by Fleet's over-the-counter laxatives. See Diana Suchetka, "Settlement Coming in Suit Concerning Oral Laxatives," The Plain Dealer, May 19, 2010. C.B. Fleet Co. was the manufacturer of Fleet Phospho-Soda and Fleet Phospho soda EZ Prep Bowel Cleansing system.
The article attributed the following statements to C.B. Fleet: "While we are encouraged by the progress made to date on the global settlement, there are several matters remaining to be resolved." "Fleet hopes that a conclusion can be reached soon that serves as a positive outcome for all concerned."
Fleet Phospho-Soda and Fleet Phospho soda EZ Prep Bowel Cleansing System were over-the-counter products used for bowel cleansing to prepare for a colonoscopy. These products were recalled from the market after the FDA issued a safety alert on December 11, 2008, warning that they can cause kidney failure (renal failure). Side effects include dialysis and the need for a kidney transplant.
You may have a strong legal claim if you or a loved one used one of these products before a colonoscopy, suffered kidney damage or a kidney injury shortly after the colonoscopy, including later requiring dialysis or a kidney transplant. Contact the Fleet injury attorneys at DeCarli Law for a free, no obligation consultation. As is often the case with legal claims, a short deadline may apply to your claim, so please contact us as soon as possible if you believe you suffered a Fleet kidney injury or Fleet kidney damage.
UPDATE: As of August 1, 2010, DeCarli Law is no longer accepting new cases for people injured by Fleet Phospho-Soda or Fleet Phospho soda EZ Prep Bowel Cleansing System.
|
|
| Continue reading "The Cleveland Plain Dealer Reports Fleet Settlement Coming Soon" » |
|
Permalink  |
| |
| February 09, 2010 |
| Rapamycin a Possible Treatment for Nephrogenic Systemic Fibrosis (NSF) |
| Posted By DeCarli Law |
|
The immunosuppressant drug
rapamycin, also known as
sirolimus, may help improve the symptoms of
nephrogenic systemic fibrosis (NSF), according to a Case Report published in the February 2010 Journal of the
American Academy of Dermatology.
NSF is a fibrosing disorder caused by the use of
gadolinium-based contrast agents on patients with impaired kidney (renal) function. Some
NSF patients have seen a slowing of the progression of the disease, or even improvement, after kidney transplants. The Case Report indicates that the improvement may result from the immunosuppressant drugs used as part of the transplant procedure.
The Case Report notes that rapamycin targets a protein related to another protein found in the fibrocytes associated with
NSF. An
NSF patient was treated with rapamycin, and after three weeks, experienced a “dramatic” decrease of the swelling, hardening and pain in his lower legs. A complete copy of the Case Report may be obtained
HERE
.
Because there is still no cure for
NSF, another possible treatment is welcome news, complementing other
NSF treatment options. NSF treatments are still experimental and expensive. If you or someone you know has
NSF, you may have a legal claim. Contact the NSF attorneys/MRI lawyers at DeCarli Law for a free, no-obligation consultation, to learn more about your legal rights and the possibility of receiving compensation for your injury.
|
|
| Continue reading "Rapamycin a Possible Treatment for Nephrogenic Systemic Fibrosis (NSF)" » |
|
| Permalink |
| |
| January 08, 2010 |
| Dialysis or Kidney Transplant After Colonoscopy |
| Posted By DeCarli Law |
|
If you began having serious kidney problems just weeks after a colonoscopy, the cause may have been the Fleet Phospho-Soda or Fleet Phospho soda EZ Prep Bowel Cleansing System you used before your colonoscopy.
Fleet Phospho-Soda and Fleet Phospho soda EZ Prep Bowel Cleansing System were over-the-counter products recommended to cleanse the bowels before a colonoscopy. They are a type of oral sodium phosphate or “OSP.” The FDA issued a safety alert on December 11, 2008, warning that OSPs can cause kidney failure (renal failure), and the Fleet products were recalled from the market. Side effects include dialysis and the need for a kidney transplant.
If you or a loved one used one of these products before a colonoscopy, and are now on dialysis or were forced to have a kidney transplant, you may have a strong legal claim. Contact the attorneys at DeCarli Law for a free, no obligation consultation. As is often the case with legal claims, a short deadline may apply to your claim, so please contact us as soon as possible if you believe you were injured by Fleet Phospho-Soda or Fleet Phospho soda EZ Prep Bowel Cleansing System.
UPDATE: As of August 1, 2010, DeCarli Law is no longer accepting new cases for people injured by Fleet Phospho-Soda or Fleet Phospho soda EZ Prep Bowel Cleansing System.
|
|
| Continue reading "Dialysis or Kidney Transplant After Colonoscopy" » |
|
| Permalink |
| |
| November 17, 2009 |
| FDA Staff: Omniscan, Magnevist and OptiMARK Gadolinium-Based Contrast Agents Most Likely to Cause NSF |
| Posted By DeCarli Law |
|
In a recently-prepared FDA document, staff members conclude that Omniscan, Magnevist, and OptiMARK are the gadolinium-based contrast agents with the highest risk of causing Nephrogenic Systemic Fibrosis (NSF). A much lower NSF risk is associated with Prohance and Multihance. These conclusions are contained in a briefing document prepared for an upcoming FDA committee meeting that will consider changing the warning labels to reflect these differing risks.
The briefing document was prepared for an Advisory Committee meeting to be held on December 8, 2009, which will re-evaluate the current warnings required for gadolinium-based contrast agents. Currently, all gadolinium-based contrast agents must have the same warning, regardless of brand. This decision was made in 2007, based on the information available at that time about NSF. However, the warning labels may change if the recommendations of FDA staff members are adopted.
Various FDA staff reports contained in the briefing document recommend heightened warning labels for the three more dangerous contrast agents: Omniscan, Magnevist, and OptiMARK. A lesser warning would be required for Prohance and Multihance, which are associated with fewer cases of NSF. In fact, the makers of Optimark have already changed their warning label on their own, as reported in a previous blog post, contraindicating use of their product for patients with severe renal disease and those awaiting a liver transplant.
The FDA documents provide further support for what has already become apparent in NSF lawsuits: most people develop NSF after exposure to Omniscan, Magnevist, and OptiMARK.
If you or someone you know has developed Nephrogenic Systemic Fibrosis (NSF) after exposure to gadolinium-based contrast agents during an MRI or other medical procedure, consider contacting the MRI lawyers at DeCarli Law for a free, no obligation consultation.
|
|
| Continue reading "FDA Staff: Omniscan, Magnevist and OptiMARK Gadolinium-Based Contrast Agents Most Likely to Cause NSF" » |
|
| Permalink |
| |
| November 04, 2009 |
| UV-A1 Therapy Promising for Nephrogenic Systemic Fibrosis (NSF) |
| Posted By DeCarli Law |
|
A recent study indicates that UV-A1 phototherapy has promise for reducing symptoms of Nephrogenic Systemic Fibrosis (NSF). Four patients with NSF were treated with UV-A1. The skin on all four softened, and for two, their hand and leg mobility improved.
The study was conducted by the Dermatology Department of the University of Texas Southwestern Medical Center, in Dallas. All four patients had NSF and were undergoing hemodialysis. They were treated with a UV-A1 bed with varying levels of radiation depending on their complexion. UVA radiation has a long wavelength that enables it to reach the subcutis (the connective tissue beneath the skin).
After treatment, the effected areas of the skin on all four of the patients became less hard, and had decreased pain and itching. Two had increased joint mobility, resulting in an enhanced quality of life. Significantly, their improvements appeared to last. The patients were tracked for varying lengths of time after treatment (six months to one year), and their improved skin condition and mobility lasted during those periods. This is very promising, since the improvements from other experimental treatments appear far more temporary.
You may obtain a complete copy of this study HERE. Tran, et al., “UV-A1 Therapy for Nephrogenic Systemic Fibrosis,” Archives of Dermatology, Vol. 145, No. 10, Oct. 2009, pp. 1170-1182.
Nephrogenic systemic fibrosis (NSF) is a disease characterized by hardening of the skin and other tissue caused by exposure to a gadolinium-based contrast agent. Dialysis patients and others with renal failure (kidney failure) are at greatest risk for this MRI side effect. If you have been diagnosed with NSF or are experiencing symptoms of NSF (hardening of the skin, joint pain), you may have a legal claim against the manufacturer of the contrast agent used in your treatment. Contact the MRI lawyers/NSF attorneys at DeCarli Law for a free consultation.
|
|
| Continue reading "UV-A1 Therapy Promising for Nephrogenic Systemic Fibrosis (NSF)" » |
|
| Permalink |
| |
| October 01, 2009 |
| The Term "MRI Lawsuit" is Misleading |
| Posted By Bob DeCarli |
|
An internet search for the phrase “MRI lawsuit” will pull up various law-firm and attorney-sponsored websites. The term “MRI lawsuit,” however, is misleading. Magnetic resonance imaging (MRI) itself does not cause nephrogenic systemic fibrosis (NSF), also known as nephrogenic fibrosing dermopathy (NFD).
The real culprits are gadolinium-based contrast agents. An injection of a gadolinium-based contrast agent -- even just one -- can cause NSF/NFD. These contrast agents are used in some, but not all, MRIs. If nothing was injected into you for your MRI, you did not receive a gadolinium-based contrast agent and therefore are not at risk of developing NSF. Further, gadolinium-based contrast agents are also used in medical scans other than MRIs, despite the fact that the FDA has not approved their use in these treatments. These unapproved uses include the following: MRA, angiogram/angioplasty, CT scan (CAT scan), fistulogram, and venogram.
So you cannot bring a lawsuit merely because you had an MRI. You may, however, have a strong legal claim if you have developed nephrogenic systemic fibrosis (NSF) after receiving an injection of a gadolinium-based contrast agent for an MRI or other medical scan. No matter what you call them -- MRI lawsuits, NSF lawsuits, or gadolinium lawsuits -- the attorneys at DeCarli Law can handle them. Call for a free consultation.
|
|
| Continue reading "The Term "MRI Lawsuit" is Misleading" » |
|
| Permalink |
| |
| 6 entries found. Viewing page 1 of 1. |
| | |
|
 |